Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythaemia: measuring the uncertain

Panayiotis D. Ziakas
Bone Marrow Transplantation Unit, ‘Hygeia’ Diagnostic & Therapeutic Centre, Athens, Greece

Citation: Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythaemia: measuring the uncertain. Haematologica 2008. doi: 10.3324/haematol.12970

Supplementary Table S2. Effect of JAK2 V617F on venous thrombosis (a), arterial thrombosis (b) and thrombosis at presentation (c). Data pooled from 1330, 1330 and 1285 ET patients, respectively.

<table>
<thead>
<tr>
<th>Study</th>
<th>Thrombosis (a)</th>
<th>Thrombosis (b)</th>
<th>Thrombosis at Presentation (c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonomi et al. 2007</td>
<td>1.78</td>
<td>1.78</td>
<td>1.78</td>
</tr>
<tr>
<td>Kitchin et al. 2005</td>
<td>1.83</td>
<td>1.83</td>
<td>1.83</td>
</tr>
<tr>
<td>O'Reilly et al. 2007</td>
<td>1.83</td>
<td>1.83</td>
<td>1.83</td>
</tr>
<tr>
<td>Vannucchi et al. 2007</td>
<td>1.83</td>
<td>1.83</td>
<td>1.83</td>
</tr>
<tr>
<td>Antin et al. 2006</td>
<td>1.78</td>
<td>1.78</td>
<td>1.78</td>
</tr>
</tbody>
</table>

Total 76% CI: 1.67
Total events: Venous thrombosis (a) (vJAK2 positive) / arterial thrombosis (b) / Thrombosis at presentation (c) = 190

0.1 0.2 0.3 0.4 0.5

Appendix

- Cheung B, Radia D, Pantelidis P, Yadaegarz F, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006;132:244.